Law360 (May 20, 2010, 12:58 PM EDT) -- Brazil's antitrust enforcer has given its blessing to Sanofi-Aventis SA's €500 million ($635 million) acquisition of Medley Pharmaceuticals Ltd., provided the Brazilian drug company gives up rights to three of its branded drugs.
Medley will have to sell off gastrointestinal treatments Digedrat and Peridal and vascular treatment Lopigrel in order to preserve competition in the country's pharmaceutical industry, Brazil's Administrative Council for Economic Defense, or CADE, said Wednesday.
Without the divestitures, the newly merged drugmaker would have a 54 percent share of the market for gastrointestinal treatments and a 62.9 percent hold over the market for heart attack and stroke treatments,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!